Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)

Summary by Seeking Alpha
AbbVie shares: Phase 1 data for weekly ABBV-295 amylin analog shows up to ~10% weight loss, supporting Phase 2 plans—read the key results now.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)

AbbVie shares: Phase 1 data for weekly ABBV-295 amylin analog shows up to ~10% weight loss, supporting Phase 2 plans—read the key results now.

·Ra'anana, Israel
Read Full Article
stocktitan.netstocktitan.net

AbbVie’s experimental weight-loss drug cut body weight 7.9% with monthly doses over 13 weeks

Nausea was reported by 33.3% of ABBV-295 recipients versus 20% on placebo; findings support Phase 2 development, but safety and efficacy remain unestablished.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Wednesday, September 30, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

North Chicago icon

North Chicago

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal